Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach

Hepatology

Volumn 65, Issue 2, 2017, Pages 451-464

  Del Chierico, Federica ^a   Nobili, Valerio ^a   Vernocchi, Pamela ^a   Russo, Alessandra ^a   Stefanis, Cristiano De ^a   Gnani, Daniela ^a   Furlanello, Cesare ^b   Zandonà, Alessandro ^b   Paci, Paola ^c,d   Capuani, Giorgio ^e   Dallapiccola, Bruno ^a   Miccheli, Alfredo ^e   Alisi, Anna ^a   Putignani, Lorenza ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b FONDAZIONE BRUNO KESSLER   (Italy)

^c CNR   (Italy)

^d SysBio Centre for Systems Biology   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTANONE; 4 METHYL 2 PENTANONE; BUTANOL; RNA 16S; VOLATILE ORGANIC COMPOUND;

ACNE; ACTINOBACTERIA; ADOLESCENT; ANAEROCOCCUS; ARTICLE; BACTEROIDES FRAGILIS; BACTEROIDETES; BLAUTIA; BRADYRHIZOBIUM; CHILD; CHILDHOOD DISEASE; CHILDHOOD OBESITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; FECES; FECES ANALYSIS; FEMALE; GENETIC VARIABILITY; HUMAN; INTESTINE FLORA; LACHNOSPIRACEAE; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; METAGENOMICS; MICROBIAL DIVERSITY; NONALCOHOLIC FATTY LIVER; PARABACTEROIDES; PEPTONIPHILUS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PYROSEQUENCING; RIKENELLACEAE; RUMINOCOCCUS; SOLID PHASE MICROEXTRACTION; UPREGULATION; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; FATTY LIVER; GENETICS; MICROBIOLOGY; MULTIVARIATE ANALYSIS; OBESITY; PATHOPHYSIOLOGY; PEDIATRICS; PROCEDURES; PROTEOGENOMICS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHILD; FATTY LIVER; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PEDIATRICS; PROTEOGENOMICS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 84971663701     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28572     Document Type: Article

References (42)

1. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol 2015;1:275-284.
2. Mehal WZ. The gut–liver axis: a busy two-way street. Hepatology 2012;55:1647-1649.
3. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012;22:471-476.
4. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009;87:679-695.
5. Abu-Shanab A, Quigley EMM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:691-701.
6. Vanni E, Bugianesi E. The gut–liver axis in nonalcoholic fatty liver disease: another pathway to insulin resistance? Hepatology 2009;49:1790-1792.
7. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211.
8. Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012;30:158-162.
9. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
10. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010;11:430-445.
11. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842-845.
12. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-609.
13. Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res 2015;77:245-251.
14. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013;19:338-348.
15. Bajaj JS, Hylemon PB, Younossi Z. The intestinal microbiota and liver disease. Am J Gastroenterol Suppl 2012;1:9-14.
16. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012;303:G675-G685.
17. Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012;2:132.
18. Burcelin R. Regulation of metabolism: a cross talk between gut microbiota and its human host. Physiology (Bethesda) 2012;27:300-307.
19. Vajro P, Paolella G, Fasano A. Microbiota and gut–liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013;56:461-468.
20. Burcelin R, Serino M, Chabo C, Garidou L, Pomié C, Courtney M, et al. Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes Obes Metab 2013;15(Suppl. 3):61-70.
21. Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, et al. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci 2014;15:684-711.
22. Biesecker LG. Hypothesis-generating research and predictive medicine. Genome Res 2013;23:1051-1053.
23. Martens H, Martens M. Modified jack-knife estimation of parameter uncertainty in bilinear modelling by partial least squares regression (PLSR). Food Qual Prefer 2000;11:5-16.
24. Martens H, Anderssen E, Flatberg A, Gidskehaug LH, Høy M, Westad F, et al. Regression of a data matrix on descriptors of both its rows and of its columns via latent variables: L-PLSR. Comput Stat Data Anal 2005;48:103-123.
25. Wold S, Høy M, Martens H, Trygg J, Westad F, MacGregor J, et al. The PLS model space revisited. J Chemom 2009;23:67-68.
26. Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans. Philadelphia, PA: Society for Industrial and Applied Mathematics; 1982.
27. Benjamini Y, Hocberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300.
28. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
29. Watson SB, Mccauley E, Downing JA. Patterns in phytoplankton taxonomic composition across temperate lakes of differing nutrient status. Limnol Oceanogr 1997;42:487-495.
30. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868-875.
31. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;139:1844-1854.
32. Lam YY, Ha CWY, Campbell CR, Mitchell AJ, Dinudom A, Oscarsson J, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 2012;7:e34233.
33. Mondot S, Kang S, Furet JP, Aguirre de Carcer D, McSweeney C, Morrison M, et al. Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis 2011;17:185-192.
34. Claesson MJ, O'Sullivan O, Wang Q, Nikkilä J, Marchesi JR, Smidt H, et al. Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PloS One 2009;4:e6669.
35. Tims S, Derom C, Jonkers DM, Vlietinck R, Saris WH, Kleerebezem M, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J 2013;7:707-717.
36. Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2015;91:1-9.
37. Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLOS Pathog 2015;11:e1004559.
38. Fernández Del Río R, O'Hara ME, Holt A, Pemberton P, Shah T, Whitehouse T, et al. Volatile biomarkers in breath associated with liver cirrhosis—comparisons of pre- and post-liver transplant breath samples. EBioMedicine 2015;2:1243-1250.
39. Van den Velde S, Nevens F, Van Hee P, van Steenberghe D, Quirynen M. GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci 2008;875:344-348.
40. Patel RN, Hou CT, Laskin AI, Derelanko P, Felix A. Microbial production of methyl ketones. Purification and properties of a secondary alcohol dehydrogenase from yeast. Eur J Biochem 1979;101:401-406.
41. Hou CT, Patel R, Laskin AI, Barnabe N. Microbial oxidation of gaseous hydrocarbons: epoxidation of C2 to C4 n-alkenes by methylotrophic bacteria. Appl Environ Microbiol 1979;38:127-134.
42. Mathews JM, Raymer JH, Etheridge AS, Velez GR, Bucher JR. Do endogenous volatile organic chemicals measured in breath reflect and maintain CYP2E1 levels in vivo? Toxicol Appl Pharmacol 1997;146:255-260.